Digest Network Come funziona
Network
/
Società
Bi
Non verificato

Biocytogen

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

7 comunicati stampa

Guarda tutti i comunicati
28/02/2026
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Fonte
Biocytogen
Emittente
Business Wire
1.00
0
09/01/2026
Mercato del lavoro
Industria
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
Fonte
Biocytogen
Emittente
Business Wire
1.00
0
17/06/2025
Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
Fonte
Biocytogen
Emittente
Business Wire
1.00
0
09/01/2025
Mercato del lavoro
Industria
Scienza
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Farmaceutica
Salute
Oncologia
Biocytogen Announces Licensing of Fully Human Antibodies with SOTIO to Develop Novel ADC SOT109 for Colorectal Cancer Treatment
Fonte
Biocytogen
Emittente
Business Wire
1.00
0
07/01/2025
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Fonte
Biocytogen
Emittente
Business Wire
1.00
0
07/01/2025
Mercato del lavoro
Industria
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Fonte
Biocytogen
Emittente
Business Wire
1.00
0
16/07/2024
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
Fonte
Biocytogen
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0